Clinical Trial

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-11-17; most recent amendment 2026-06-04.
Status change: Not Yet Recruiting → Recruiting 2026-01-06
Trial Details
NCT Number NCT07235293
Lead Sponsor Kahr Bio Australia Pty Ltd
Collaborators: Novotech (Australia) Pty Limited
Conditions Colorectal Cancer
Enrollment 90 participants
Start Date 2026-01-16
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12